Yes, rheumatoid arthritis itself makes you immunocompromised in the clinical sense: it is an autoimmune disease in which your immune system attacks joint tissue, and the disease plus its treatments impair normal immune defense. That impairment is partial, variable, and different from the combined immunodeficiency of advanced HIV or post-transplant immunosuppression.
The short answer hides real complexity. "Immunocompromised" is not a single on-off switch. It is a spectrum of reduced capacity to contain infection, and rheumatoid arthritis (RA) places most patients somewhere on that spectrum. This explainer walks through the mechanism, the quantified risk, the edge cases that buck the pattern, and what the label means for everyday decisions.
Two immune failures, one disease
RA is not a weak immune system in the way people usually mean. It is a misdirected one. The adaptive immune system generates antibodies and T cells that recognize citrullinated proteins, self-proteins altered by an enzyme called PAD. These autoantibodies, chiefly anti-cyclic citrullinated peptide (anti-CCP) and rheumatoid factor, form immune complexes that deposit in the synovium. That triggers complement activation and recruits neutrophils and macrophages into the joint.
The result is a chronic inflammatory loop. Cytokines such as tumor necrosis factor (TNF), interleukin-6 (IL-6), and interleukin-1 drive tissue destruction and systemic inflammation. This same loop slowly degrades the parts of immunity that fight infection. Chronic inflammation exhausts T cells, skews them toward a dysfunctional state, and impairs the lymph-node architecture where immune responses are organized. A body at war with itself has less capacity to fight invaders.
So RA produces immunodeficiency by two routes. The disease itself distorts immune function. The drugs used to control it suppress the specific pathways infection defense depends on. The next section examines what those drugs actually do.
How RA drugs disarm infection defense
Each major drug class blocks a specific immune function, and the infection risk each carries reflects exactly which function is lost. Methotrexate inhibits dihydrofolate reductase and interferes with purine synthesis, slowing the rapid cell division that T cells and B cells depend on to mount a response. It also nudges cells toward releasing adenosine, which dampens inflammation. The net effect is a quieter, slower adaptive response.
TNF inhibitors bind and neutralize TNF, a cytokine essential for forming granulomas, the cellular cages that wall off tuberculosis bacteria and similar pathogens. Blocking TNF can let latent tuberculosis reactivate, which is why screening before starting these drugs is standard. IL-6 inhibitors block a cytokine that coordinates fever and acute-phase responses; patients on these drugs may not mount a normal fever, which can mask serious infection. B-cell depletion with rituximab removes the cells that produce antibodies, lowering vaccine responses and long-term humoral protection.
Janus kinase (JAK) inhibitors work inside the cell, blocking signaling downstream of multiple cytokines at once. Because that pathway feeds natural killer cells and interferon responses, JAK inhibitors suppress antiviral defense broadly. Glucocorticoids (steroids) remain the most consistently risky class: they suppress nearly every arm of immunity in a dose-dependent way. The higher the daily dose, the larger the infection signal, and the risk persists long after the prescription stops.
Quantified risk: how much does it actually rise?
The baseline matters before the multiplier. People with RA carry an elevated risk of serious infection compared with the general population even before any drug is counted, driven by the disease's inflammatory burden and by lung involvement common in RA. On top of that baseline, each treatment adds its own increment.
Serious infections requiring hospitalization occur more often in RA cohorts than in age-matched controls. The exact multiplier varies by study design and population, so treat any single figure as an estimate rather than a fixed constant. Across the drug classes, the pattern is consistent: steroid exposure carries the largest and most dose-dependent increase, TNF inhibitors and other biologics carry a moderate increase, and conventional disease-modifying drugs such as methotrexate carry a smaller increment when used alone.
Absolute risk also climbs with age, with the presence of lung disease, and with the number of immunosuppressive drugs stacked together. A 70-year-old with RA-related interstitial lung disease on a biologic plus low-dose steroid faces a meaningfully different risk than a 35-year-old on methotrexate alone. That is why the label "immunocompromised" should be read as a personal, layered estimate rather than a category.
| Factor | Effect on infection risk | Relative weight |
|---|---|---|
| Active RA inflammation (untreated) | Elevated vs. general population | Baseline increase |
| Low-dose methotrexate alone | Small increase | Low |
| TNF inhibitor | Moderate increase; TB reactivation risk | Moderate |
| IL-6 inhibitor | Moderate; may blunt fever | Moderate |
| Rituximab (B-cell depletion) | Reduced antibody responses | Moderate to high |
| JAK inhibitor | Broad antiviral suppression | Moderate to high |
| Glucocorticoids (higher daily dose) | Largest, dose-dependent increase | High |
These are directional patterns from cohort and registry data, not universal constants. Individual risk depends on dose, duration, age, and comorbidity.
The vaccine response problem
Immunocompromise in RA shows up most clearly in how the body handles vaccination. Live vaccines, such as live attenuated influenza or yellow fever, are generally avoided in patients on significant immunosuppression because a weakened immune system can let the vaccine organism replicate. Inactivated and mRNA vaccines are safe but may produce weaker responses.
Patients on methotrexate or biologics often mount lower antibody titers after influenza and pneumococcal vaccination than healthy peers. That does not mean vaccination fails; it means protection may be partial and boosters matter more. Rituximab is the extreme case: B-cell depletion can nearly abolish the antibody response to a vaccine for months, so timing vaccination relative to infusions becomes a real clinical decision. Corticosteroids at higher daily doses similarly blunt vaccine responses.
The counterintuitive detail: some immunosuppressive therapy can be temporarily paused around vaccination to improve the response, but the decision is drug-specific and must involve the treating clinician. Pausing is not automatically right, and mistimed pauses can trigger a disease flare that is itself harmful. The reasonable takeaway is that vaccine timing is a shared decision, not a rule of thumb.
When the label does not fit: edge cases and caveats
A patient with well-controlled RA on low-dose methotrexate has a modestly increased infection risk, not a severely disabled immune system. Calling that person "immunocompromised" in the same breath as a transplant recipient overstates the risk and can cause unnecessary anxiety or overcaution. Conversely, a patient on a JAK inhibitor plus chronic steroids plus rituximab may be substantially more vulnerable than a generic label suggests.
Disease activity itself is a confounder. Patients with highly active, untreated RA have elevated infection rates, which means some of the risk attributed to "having RA" reflects uncontrolled inflammation rather than the disease per se. Effective treatment that controls inflammation may partly offset the risk added by the drugs, which is one reason the risk picture is not simply "more drugs equals more danger."
Another caveat: the immunocompromise is partial and dynamic. It changes with flares, with dose adjustments, and with time since the last rituximab infusion. A snapshot label misrepresents a moving target. Clinicians who manage RA think in terms of current regimen, current disease activity, and current comorbidities rather than a fixed category.
Red flags and practical steps
Recognizing infection early matters more in RA because fevers may be blunted and symptoms may be attributed to the disease. Watch for:
Fever, or the absence of fever despite feeling systematically unwell on IL-6 or steroid therapy. New or worsening cough, especially with breathlessness, given RA lung involvement. A single joint that becomes hot, swollen, and far more painful than usual, suggesting septic arthritis rather than a flare. Skin redness spreading rapidly, or wounds that will not heal. Confusion or sudden fatigue in older patients, which can signal infection without classic signs.
Practical actions worth discussing with a rheumatologist:
Confirm vaccination status for influenza, pneumococcal, and other inactivated vaccines, and ask whether timing should be coordinated with drug dosing. Get screened for latent tuberculosis and hepatitis B before starting a TNF inhibitor or JAK inhibitor, as guidelines require. Report any suspicion of infection promptly rather than waiting for a scheduled visit. Avoid live vaccines unless a clinician specifically clears them. Keep an updated medication list, because the infection risk picture depends heavily on the exact regimen. Ask whether steroid dose can be minimized, since that is the most modifiable risk lever.
What the evidence cannot tell you
Population studies describe averages; they cannot predict an individual's course. The risk multipliers in the table above come from cohorts with different designs, different definitions of serious infection, and different follow-up windows. Comparing them head-to-head is imprecise. Registry data usually capture serious infections requiring hospitalization but miss milder ones, and they struggle to separate drug effects from disease severity.
There is also a genuine evidence gap on long-term immune recovery. Antibody levels and infection risk after stopping a biologic vary by drug and by patient, and the timelines are not well standardized. What can be said confidently is that the immunocompromise in RA is real, partial, mechanism-specific, and modifiable at the margins through vaccination, steroid minimization, and prompt infection reporting. What cannot be said is that any single number captures a given patient's risk.